 Phase 2a trial meets enrollment target for interim analysis and is now more than 50 enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90 of patients completing the trial have opted into the Open Label Extension study ZURICH, SWITZERLAND ACCESSWIRE February 7, 2022 NLS Pharmaceutics Ltd. NASDAQ:NLSP, NLSPW NLS or the Company, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it will present interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience Mazindol ER, for the treatment of narcolepsy at this years World Sleep Congress World Sleep 2022, taking place in Rome, Italy March 11-16, 2022. 